Clinical efficacy of Xifeng Huashi and its effect on mental status in patients with diarrheal irritable bowel
Wei Wang1,2, Hui Li1, Yu-Ping Liu3
1Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
Background:
Diarrheal irritable bowel syndrome (IBS-D) is a functional gastrointestinal disorder characterized by abdominal pain accompanied by recurrent diarrhea that significantly impacts the quality of life and mental health of patients.
Aim:
To investigate the clinical efficacy of Xifeng Huashi and its effects on the mental status of patients diagnosed with IBS-D.
Methods:
Data from 128 patients with IBS-D treated at the Nanjing University of Chinese Medicine Affiliated Hospital of Integrated Traditional Chinese and Western Medicine between June 2023 and May 2024 were divided into control and research groups, with 64 patients in each group. The control group received conventional treatment with Western medicine alone, whereas the research group was prescribed Xifeng Huashi. Differences in specific indices between the two groups were observed and compared using relevant assessment tools.
Results:
The research group showed a higher total effective rate (92.19% vs 76.56%; P = 0.027) and lower traditional Chinese medicine symptom score (5.07 ± 3.11 vs 7.38 ± 3.68; P < 0.001) than the control group. Post-treatment, the research group exhibited significantly lower levels of pro-inflammatory cytokines (tumor necrosis factor-α: 18.80 ± 4.02 ng/L vs 21.09 ± 4.10 ng/L, P = 0.002; interleukin-6:14.84 ± 4.06 ng/L vs 19.80 ± 4.42 ng/L, P < 0.001) and higher levels of the anti-inflammatory cytokine interleukin-10 (48.53 ± 5.02 ng/L vs 46.06 ± 4.94 ng/L, P = 0.006). Moreover, markers of intestinal mucosal barrier function (diamine oxidase: 6.53 ± 2.35 ng/mL vs 7.66 ± 2.40 ng/mL, P = 0.008; D-lactate: 0.18 ± 0.04 mmol/L vs 0.20 ± 0.06 mmol/L, P = 0.004; lipopolysaccharides: 44.77 ± 8.16 pg/mL vs 48.20 ± 8.15 pg/mL, P = 0.019) were significantly improved in the research group. In addition, Self-rating Anxiety Scale (37.33 ± 5.73 vs 39.59 ± 6.36; P = 0.036) and Self-rating Depression Scale scores (34.77 ± 6.71 vs 38.06 ± 6.52; P = 0.006) were lower in the research group. The recurrence rate was significantly lower in the research group than in the control group (18.64% vs 40.82%, P = 0.001).
Conclusion:
Xifeng Huashi is effective for the treatment of IBS-D and manifests advantages in improving clinical symptoms and mental status, as well as reducing the short-term relapse rate.
More Related Videos
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:30Stress and Mental Health
Individuals with depression often experience challenges in both their personal and professional...
01:29Self-Efficacy
01:10Higher Mental Functions of the Brain: Language
Language formation and comprehension take place in the dominant hemisphere. The dominant hemisphere is responsible for understanding the meaning of spoken, written, or sign language, as well as the ability to communicate. For most people, the left hemisphere is the dominant one. The right hemisphere, then, gives tone and emotional context to the...